1445155-39-4

1445155-39-4 structure

Name: MR 409
Chemical Name: MR 409
CAS Number: 1445155-39-4
Molecular Formula: C₁₅₃H₂₅₂N₄₄O₄₃
Molecular Weight: 3395.91
Catalog: Research Areas Cancer
Create Date: 2022-03-28 17:10:38
Modify Date: 2024-01-03 14:34:21
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].

Name	MR 409

Description	MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
In Vitro	One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1]. MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2]. MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2]. MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3]. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3]. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3]. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4]. Western Blot Analysis[2] Cell Line: BPAEC Concentration: 1 μM Incubation Time: 24, 48 and 72 hours Result: Significantly suppressed p53 expression levels after 48 and 72 hours of treatment.
In Vivo	MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice[3]. MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3]. Animal Model: Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)[3] Dosage: 5 µg Administration: Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution Result: Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.
References	[1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. [2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989. [3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530. [4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118.

Molecular Formula	C₁₅₃H₂₅₂N₄₄O₄₃
Molecular Weight	3395.91

1445155-39-4	62509-10-8
185213-55-2	61849-16-9
2374703-19-0	61849-15-8
185308-24-1	147614-21-9
207403-36-9	59203-73-5
1158522-08-7	940364-43-2
1806724-62-8	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	1780998-28-8